These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 35690010

  • 1. Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
    Rolfes L, Pfeuffer S, Huntemann N, Schmidt M, Su C, Skuljec J, Aslan D, Hackert J, Kleinschnitz K, Hagenacker T, Pawlitzki M, Ruck T, Kleinschnitz C, Meuth SG, Pul R.
    Mult Scler Relat Disord; 2022 Aug; 64():103931. PubMed ID: 35690010
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    Zanetta C, Rocca MA, Meani A, Martinelli V, Ferrè L, Moiola L, Filippi M.
    J Neurol; 2023 Jul; 270(7):3553-3564. PubMed ID: 37027018
    [Abstract] [Full Text] [Related]

  • 3. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G, Cook S, Giovannoni G, Rieckmann P, Sørensen PS, Vermersch P, Galazka A, Nolting A, Hicking C, Dangond F.
    Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
    [Abstract] [Full Text] [Related]

  • 4. Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort.
    Aerts S, Khan H, Severijns D, Popescu V, Peeters LM, Van Wijmeersch B.
    Mult Scler Relat Disord; 2023 Jul; 75():104735. PubMed ID: 37192586
    [Abstract] [Full Text] [Related]

  • 5. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
    Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E.
    Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374
    [Abstract] [Full Text] [Related]

  • 6. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
    Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ, CLARITY Study Group.
    Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
    [Abstract] [Full Text] [Related]

  • 7. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
    Brochet B, Hupperts R, Langdon D, Solari A, Piehl F, Lechner-Scott J, Montalban X, Selmaj K, Valis M, Rejdak K, Havrdova EK, Patti F, Alexandri N, Nolting A, Keller B.
    Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
    [Abstract] [Full Text] [Related]

  • 8. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS, Pontieri L, Joensen H, Heick A, Rasmussen PV, Schäfer J, Ratzer R, Pihl CE, Sellebjerg F, Magyari M.
    Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
    [Abstract] [Full Text] [Related]

  • 9. Safety and Effectiveness of Cladribine in Multiple Sclerosis: Real-World Clinical Experience From 5 Tertiary Hospitals in Portugal.
    Santos M, Sequeira J, Abreu P, Guerreiro R, Santos M, Ferreira J, Brum M, Ladeira F, Leitão L, Dias R, Sá MJ, Salgado V, Capela C, de Sá J.
    Clin Neuropharmacol; 2023 Feb; 46(3):105-111. PubMed ID: 37191564
    [Abstract] [Full Text] [Related]

  • 10. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis.
    Leist T, Cook S, Comi G, Montalban X, Giovannoni G, Nolting A, Damian D, Syed S, Galazka A.
    Mult Scler Relat Disord; 2020 Nov; 46():102572. PubMed ID: 33296971
    [Abstract] [Full Text] [Related]

  • 11. Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets.
    Giovannoni G, Coyle PK, Vermersch P, Walker B, Aldridge J, Nolting A, Galazka A, Lemieux C, Leist TP.
    Front Immunol; 2021 Nov; 12():763433. PubMed ID: 35003076
    [Abstract] [Full Text] [Related]

  • 12. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
    Stępień A, Pogoda-Wesołowska A, Tokarz-Kupczyk E, Słowik A, Puz P, Adamczyk-Sowa M, Kurkowska-Jastrzębska I, Kułakowska A, Chorąży M, Piasecka-Stryczyńska K, Jamróz-Wiśniewska A, Bartosik-Psujek H, Rejdak K.
    Neurol Neurochir Pol; 2023 Nov; 57(4):371-378. PubMed ID: 37490356
    [Abstract] [Full Text] [Related]

  • 13. Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
    Adamec I, Brecl Jakob G, Rajda C, Drulović J, Radulović L, Bašić Kes V, Lazibat I, Rimac J, Cindrić I, Gržinčić T, Abičić A, Barun B, Gabelić T, Gomezelj S, Mesaroš Š, Pekmezović T, Klivényi P, Krbot Skorić M, Habek M.
    J Neuroimmunol; 2023 Sep 15; 382():578164. PubMed ID: 37536052
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres.
    Pfeuffer S, Rolfes L, Hackert J, Kleinschnitz K, Ruck T, Wiendl H, Klotz L, Kleinschnitz C, Meuth SG, Pul R.
    Mult Scler; 2022 Feb 15; 28(2):257-268. PubMed ID: 33975489
    [Abstract] [Full Text] [Related]

  • 15. Cladribine to Treat Relapsing Forms of Multiple Sclerosis.
    Giovannoni G.
    Neurotherapeutics; 2017 Oct 15; 14(4):874-887. PubMed ID: 29168160
    [Abstract] [Full Text] [Related]

  • 16. Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis.
    Terranova N, Hicking C, Dangond F, Munafo A.
    Clin Pharmacokinet; 2019 Mar 15; 58(3):325-333. PubMed ID: 29992396
    [Abstract] [Full Text] [Related]

  • 17. High persistence and low adverse events burden in cladribine treated MS patients from Argentina.
    Negrotto L, Iut VC, Etchepare A, D'Eramo M, Grinspan A, Assefi A.
    Mult Scler Relat Disord; 2022 Dec 15; 68():104403. PubMed ID: 36544327
    [Abstract] [Full Text] [Related]

  • 18. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
    Dersch R, Wehrum T, Fähndrich S, Engelhardt M, Rauer S, Berger B.
    Mult Scler; 2020 Sep 15; 26(10):1264-1266. PubMed ID: 32762488
    [Abstract] [Full Text] [Related]

  • 19. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.
    Rauma I, Viitala M, Kuusisto H, Atula S, Sipilä JOT, Ryytty M, Soilu-Hänninen M, Järvinen E.
    Mult Scler Relat Disord; 2022 May 15; 61():103755. PubMed ID: 35483129
    [Abstract] [Full Text] [Related]

  • 20. [Recommendations for the use of cladribine tablets in recurring multiple sclerosis].
    Oreja-Guevara C, García-Merino JA, Saiz A, Rodríguez-Antigüedad A, Álvarez-Cermeño JC, Estrada-Pérez V, Izquierdo G, Fernández O.
    Rev Neurol; 2019 Dec 17; 69(s02):1-9. PubMed ID: 31933293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.